HK1250707B - 氮杂环丁烷衍生物、其制备方法及用途 - Google Patents
氮杂环丁烷衍生物、其制备方法及用途 Download PDFInfo
- Publication number
- HK1250707B HK1250707B HK18109969.8A HK18109969A HK1250707B HK 1250707 B HK1250707 B HK 1250707B HK 18109969 A HK18109969 A HK 18109969A HK 1250707 B HK1250707 B HK 1250707B
- Authority
- HK
- Hong Kong
- Prior art keywords
- compound
- reaction
- pyrrolo
- methyl
- mmol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510924946.1 | 2015-12-11 | ||
| CN201510924946 | 2015-12-11 | ||
| PCT/CN2016/109036 WO2017097224A1 (zh) | 2015-12-11 | 2016-12-08 | 氮杂环丁烷衍生物、其制备方法及用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HK1250707A1 HK1250707A1 (en) | 2019-01-11 |
| HK1250707B true HK1250707B (zh) | 2020-07-03 |
Family
ID=59012693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18109969.8A HK1250707B (zh) | 2015-12-11 | 2016-12-08 | 氮杂环丁烷衍生物、其制备方法及用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10159662B2 (enExample) |
| EP (1) | EP3360878B9 (enExample) |
| JP (1) | JP6860267B2 (enExample) |
| CN (1) | CN108137603B (enExample) |
| DK (1) | DK3360878T3 (enExample) |
| ES (1) | ES2830446T3 (enExample) |
| HK (1) | HK1250707B (enExample) |
| WO (1) | WO2017097224A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10159662B2 (en) * | 2015-12-11 | 2018-12-25 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Azetidine derivative, preparation method therefor, and use thereof |
| CA3055233C (en) * | 2017-01-23 | 2022-08-09 | Shanghai Longwood Biopharmaceuticals Co., Ltd. | Jak kinase inhibitor and preparation method and use thereof |
| EP3636647B1 (en) * | 2017-06-07 | 2023-01-11 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Solid form of azetidine derivative and preparation method therefor and use thereof |
| WO2019090143A1 (en) | 2017-11-03 | 2019-05-09 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrimidine-5-carboxylate analogs and methods of making the same |
| AU2018360059B2 (en) | 2017-11-03 | 2023-07-13 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyrimidine JAK inhibitors and methods of making and using the same |
| CN109867675B (zh) * | 2017-12-01 | 2021-01-19 | 北京普祺医药科技有限公司 | 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途 |
| JP6557436B1 (ja) * | 2018-03-12 | 2019-08-07 | アッヴィ・インコーポレイテッド | チロシンキナーゼ２媒介性シグナル伝達の阻害剤 |
| AU2019317625B2 (en) | 2018-08-10 | 2025-02-27 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidine ITK inhibitors |
| CN111320633B (zh) * | 2018-12-14 | 2022-09-27 | 中国医药研究开发中心有限公司 | 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途 |
| CN111518096B (zh) * | 2019-02-02 | 2022-02-11 | 江苏威凯尔医药科技有限公司 | 两面神激酶jak家族抑制剂及其制备和应用 |
| WO2020173364A1 (zh) * | 2019-02-27 | 2020-09-03 | 四川科伦博泰生物医药股份有限公司 | 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途 |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| CN113924301B (zh) | 2019-04-12 | 2024-08-16 | 北京普祺医药科技股份有限公司 | 一种吡唑并吡嗪衍生的化合物、药物组合物以及其用途 |
| US11420966B2 (en) | 2019-05-02 | 2022-08-23 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyridines as JAK inhibitors |
| CN110028432A (zh) * | 2019-05-22 | 2019-07-19 | 南京合巨药业有限公司 | 一种（3-氨基-氮杂环丁烷-1-基）-环丙基-甲酮的制备方法 |
| MX2021014361A (es) * | 2019-05-28 | 2022-04-06 | Mankind Pharma Ltd | Nuevos compuestos para la inhibición de janus quinasa 1. |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP4495118A1 (en) | 2022-03-18 | 2025-01-22 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Use and treatment method of azetidine derivative |
| WO2023226822A1 (zh) * | 2022-05-26 | 2023-11-30 | 四川科伦博泰生物医药股份有限公司 | 氮杂环丁烷衍生物治疗病毒感染的方法及用途 |
| CN115974864B (zh) * | 2022-12-29 | 2025-09-16 | 苏州汉德创宏生化科技有限公司 | 一种2-(3-氮杂环丁基)噻唑盐的合成方法 |
| WO2024148184A1 (en) * | 2023-01-04 | 2024-07-11 | Aerie Pharmaceuticals, Inc. | Compounds and processes for the preparation of jak inhibitors |
| WO2024153147A1 (zh) * | 2023-01-18 | 2024-07-25 | 北京普祺医药科技股份有限公司 | 一种氮杂环烷烃化合物、药物组合物及其用途 |
| CN116444529B (zh) * | 2023-06-16 | 2023-12-05 | 药康众拓(江苏)医药科技有限公司 | 一种氘代氮杂环丁烷类jak抑制剂及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080016659A (ko) | 2005-05-20 | 2008-02-21 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제의 억제제로서 유용한 피롤로피리딘 |
| EA017218B1 (ru) | 2008-03-11 | 2012-10-30 | Инсайт Корпорейшн | Производные азетидина и циклобутана как ингибиторы jak-киназ |
| CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| TWI531572B (zh) | 2010-03-10 | 2016-05-01 | 英塞特公司 | 作為ｊａｋ１抑制劑之哌啶－４－基三亞甲亞胺衍生物 |
| AU2012273164B2 (en) * | 2011-06-20 | 2015-05-28 | Incyte Holdings Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| US20130310340A1 (en) * | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| PL3129021T3 (pl) | 2014-04-08 | 2021-05-31 | Incyte Corporation | Leczenie nowotworów złośliwych z komórek b za pomocą skojarzenia inhibitora jak i pi3k |
| AU2016222556B2 (en) | 2015-02-27 | 2020-08-27 | Incyte Holdings Corporation | Salts of Pl3K inhibitor and processes for their preparation |
| RU2601410C1 (ru) * | 2015-11-13 | 2016-11-10 | ЗАО "Р-Фарм" | {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ |
| US10159662B2 (en) * | 2015-12-11 | 2018-12-25 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Azetidine derivative, preparation method therefor, and use thereof |
-
2016
- 2016-12-08 US US15/767,508 patent/US10159662B2/en active Active
- 2016-12-08 ES ES16872413T patent/ES2830446T3/es active Active
- 2016-12-08 DK DK16872413.6T patent/DK3360878T3/da active
- 2016-12-08 WO PCT/CN2016/109036 patent/WO2017097224A1/zh not_active Ceased
- 2016-12-08 EP EP16872413.6A patent/EP3360878B9/en active Active
- 2016-12-08 HK HK18109969.8A patent/HK1250707B/zh unknown
- 2016-12-08 CN CN201680059396.4A patent/CN108137603B/zh active Active
- 2016-12-08 JP JP2018518690A patent/JP6860267B2/ja active Active
-
2018
- 2018-10-24 US US16/169,780 patent/US20190060291A1/en not_active Abandoned
-
2020
- 2020-01-16 US US16/745,206 patent/US11045455B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3360878A4 (en) | 2019-03-06 |
| JP6860267B2 (ja) | 2021-04-14 |
| CN108137603B (zh) | 2019-10-18 |
| EP3360878A1 (en) | 2018-08-15 |
| US11045455B2 (en) | 2021-06-29 |
| WO2017097224A1 (zh) | 2017-06-15 |
| HK1251551A1 (en) | 2019-02-01 |
| US20200147062A1 (en) | 2020-05-14 |
| JP2018536634A (ja) | 2018-12-13 |
| US20190060291A1 (en) | 2019-02-28 |
| ES2830446T3 (es) | 2021-06-03 |
| EP3360878B1 (en) | 2020-09-16 |
| US10159662B2 (en) | 2018-12-25 |
| US20180289680A1 (en) | 2018-10-11 |
| CN108137603A (zh) | 2018-06-08 |
| DK3360878T3 (da) | 2020-11-09 |
| EP3360878B9 (en) | 2021-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108137603B (zh) | 氮杂环丁烷衍生物、其制备方法及用途 | |
| HK1250707A1 (en) | Azetidine derivative, preparation method therefor, and use thereof | |
| CN101365454B (zh) | 取代的4-氨基-吡咯并三嗪衍生物 | |
| CN103476767B (zh) | 作为pi3激酶抑制剂的杂环化合物 | |
| CN113637005A (zh) | 用于癌症治疗的kras抑制剂 | |
| CN115485278A (zh) | 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法 | |
| WO2024067714A1 (zh) | 具有抗kras突变肿瘤活性的化合物 | |
| CN102574847A (zh) | 作为syk激酶抑制剂的化合物和组合物 | |
| CN101765597A (zh) | 作为磷脂酰肌醇-3-激酶抑制剂的嘧啶衍生物 | |
| CN104837844B (zh) | 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪 | |
| WO2021042890A1 (zh) | 杂环化合物及其作为Trk激酶抑制剂的应用 | |
| CN112292374B (zh) | 一种新型磷酸肌醇3-激酶抑制剂及其制备方法和用途 | |
| CN106661056A (zh) | 作为酪蛋白激酶1δ/ε抑制剂的咪唑并哒嗪衍生物 | |
| CN112979655A (zh) | 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途 | |
| WO2022135590A1 (zh) | 一类嘧啶并杂环类化合物、制备方法和用途 | |
| AU2013315528A1 (en) | Aminoisoquinoline derivatives as protein kinase inhibitors | |
| CN117486890A (zh) | 三环类化合物及其用途 | |
| WO2020143763A1 (zh) | 卤代烯丙基胺类化合物及其应用 | |
| TW202028210A (zh) | 用於治療與apj受體活性相關的病狀的化合物及組成物 | |
| TW202204351A (zh) | 具有大環結構的化合物及其用途 | |
| CN115536660A (zh) | 苄氨基取代的杂多环化合物及其组合物、制剂和用途 | |
| CN109535132B (zh) | 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用 | |
| TW202313035A (zh) | Ｊａｋ２抑制劑及其使用方法 | |
| CN116969944A (zh) | 乙氨基取代的三环杂环化合物及其组合物、制剂和用途 | |
| CN118525018A (zh) | 一种联炔类化合物及其应用 |